Genetic and antigenic analysis of invasive serogroup C Neisseria meningitidis in Canada: A decrease in the electrophoretic type (ET)-15 clonal type and an increase in the proportion of isolates belonging to the ET-37 (but not ET-15) clonal type during the period from 2002 to 2009

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 23, Issue 3, 2012, Pages

  Zhou, Jianwei ^a   Jamieson, Frances ^b,c   Dolman, Sharon ^d   Hoang, Linda M N ^e   Rawte, Prasad ^b   Tsang, Raymond S W ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

^e BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

ET 15; ET 37; Meningococci; Serogroup C

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; BACTERIAL GENETICS; BACTERIUM ISOLATE; CANADA; CLONAL VARIATION; DISEASE SURVEILLANCE; GENETIC ANALYSIS; INVASIVE SPECIES; MOLECULAR CLONING; MULTILOCUS ENZYME ELECTROPHORESIS; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; SEROTYPING;

EID: 84866748043     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/131328     Document Type: Article

References (50)

1. Varughese PV, Acres S. Meningococcal disease in Canada and serogroup distribution. Can Dis Wkly Rep 1983;9:177-80.
2. Varughese PV, Carter AO. Meningococcal disease in Canada. Surveillance summary to 1987. Can Dis Wkly Rep 1989;15:89-96.
3. Ashton FE, Ryan A, Borczyk A, Caugant DA, Mancino L, Huang D. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal Group C disease in Canada. J Clin Microbiol 1991;29:2489-93.
4. National Advisory Committee on Immunization. Statement on conjugated meningococcal vaccine for serogroups A, C, Y and W135. Can Commun Dis Rep 2007;33(ACS-3):1-23.
5. Helmann, GA, Mikel DE, Naus M, et al. Meningococcal disease in Ontario during the winter of 1988-89. Can Dis Weekly Rep 1989;15:59-62.
6. De Wals P, Dionne M, Douville-Fradet M, Bouliane N, Drapeau J, De Serres G. Impact of a mass immunization campaign against serogroup C meningococcus in the province of Québec, Canada. Bull WHO 1996;74:407-11.
7. Farley JD, Osei W. Invasive meningococcal disease, British Columbia December 1991-March 1992. Can J Public Health 1992;83:138-40.
8. Sweet L. The Prince Edward Island meningococcal immunization program. January - February 1992. Can J Public Health 1992;83:138-40.
9. Tolomeo O, Buffett C, Richardson E. Management of a cluster of cases of invasive group C Neisseria meningitidis infections in the Hamilton-Wentworth Region. Can Commun Dis Rep 1998;24:122-6.
10. Whalen CM, Hockin JC, Ryan A, Ashton F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. JAMA 1995;273:390-4.
11. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States, an emerging threat. JAMA 1995;273:383-9.
12. Jelfs J, Munro R, Ashton FE, Caugant DA. Genetic characterization of a new variant within the ET-37 complex of Neisseria meningitidis associated with outbreaks in various parts of the world. Epidemiol Infect 2000;125:285-98.
13. Caugant DA, Zollinger WD, Mocca LF, et al. Genetic relationships and clonal population structure of serotype 2 strains of Neisseria meningitidis. Infect Immun 1987;55:1503-13.
14. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 1998;106:505-25. (Pubitemid 28308237)
15. Wang JF, Caugant DA, Morellli G, Koumare B, Achtman M. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis 1993;167:1320-9. (Pubitemid 23146179)
16. Vogel U, Claus H, Frosch M, Caugant DA. Molecular basis for distinction of the ET-15 clone within the ET-37 complex of Neisseria meningitidis. J Clin Microbiol 2000;38:941-2. (Pubitemid 30082722)
17. Deeks S, Kertesz D, Ryan A, Ashton F. Surveillance of invasive meningococcal disease in Canada, 1995-1996. Can Commun Dis Rep 1997;23:121-5.
18. Squires SG, Pelletier L, Mungai M, Tsang R, Collins F, Stoltz J. Invasive meningococcal disease in Canada, 1 January 1997 to December 31 1998. Can Commun Dis Rep 2000;26:177-82.
19. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977;60:673-80. (Pubitemid 8242421)
20. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: A randomized controlled trial. JAMA 1998;280:1685-9. (Pubitemid 28532992)
21. Tsang RSW, Law DKS, Henderson AM, Cameron ML, Stoltz J. Increase in serogroup C meningococcal disease in Canada is associated with antigenic changes in the protein antigens of the ET-15 clone of Neisseria meningitidis. J Infect Dis 2006;194:1791-2. (Pubitemid 44902013)
22. Pollard AJ, Tam TWS. Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep 2001;27:2-36.
23. Bettinger JA, Scheifele DW, Le Saux N, et al. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009;28:220-4.
24. Kinlin LM, Jamieson F, Brown EM, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine 2009;27:1735-40.
25. Tsang RSW, Squires SG, Zollinger WD, Ashton FE. Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001. Can J Infect Dis 2002;13:391-6. (Pubitemid 36188387)
26. Navarro C, Deeks SL, Medaglia A, Tsang RSW. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January 2004, through 31 December, 2005. Can Commun Dis Rep 2007;33:1-15.
27. Watkins RM, Deeks SL, Medaglia A, Tsang RSW. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January 2002, through 31 December, 2003. Can Commun Dis Rep 2006;32:97-106.
28. Abdillahi H, Poolman JT. Whole cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett 1987;48:367-71. (Pubitemid 18012842)
29. Selander RK, Caugant DA, Ochman H, Musser JM, Gilmour MN, Whittman TS. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. Appl Environ Microbiol 1986;51:873-84. (Pubitemid 16078577)
30. Maiden MCJ, Bygraves JA, Feil E, et al. Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998;95:3140-5. (Pubitemid 28135868)
31. Hammerschmidt, S, Muller A, Sillmann H, et al. Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): Correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol 1996;20:1211-20. (Pubitemid 26225429)
32. Hammerschmidt S, Hilse R, van Putten JP, Gerady-Schahn R, Unkmeir A, Frosch M. Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBO J 1996;15:192-8. (Pubitemid 26020400)
33. Jolley KA, Wilson DJ, Kriz P, Mcvean G, Maiden MCJ. The influence of mutation, recombination, population history, and selection on patterns of genetic diversity in Neisseria meningitidis. Mol Biol Evol 2004;22:562-9.
34. van der Ende A, Hopman CTP, Dankert J. Multiple mechanisms of phase variation of PorA in Neisseria meningitidis. Infect Immun 2000;68:6685-90. (Pubitemid 32463371)
35. Law DKS, Henderson AM, Tsang RSW. DNA sequence analysis of the PorB protein of nonserotypeable serogroup C ET-15 meningococci suggests a potential mutational hot spot on their serotype antigens. J Clin Microbiol 2004;42:2718-23. (Pubitemid 38747527)
36. Tsang RSW, Kiefer L, Law DKS, et al. Outbreak of serogroup C meningococcal disease caused by a variant of Neisseria meningitidis serotype 2a ET-15 in a community of men who have sex with men. J Clin Microbiol 2003;41:4411-4. (Pubitemid 37099717)
37. Tsang RSW, Tsai CM, Zhu P, Ringuette L, Lorange M, Law DKS. Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Québec, Canada. J Clin Microbiol 2004;42:1460-5. (Pubitemid 38500781)
38. Patrick DM, Champagne S, Goh SH, et al. Neisseria meningitidis carriage during an outbreak of serogroup C disease. Clin Infect Dis 2003;37:1183-8. (Pubitemid 37372506)
39. Kertesz D, Coulthart M, Ryan A, Johnson W, Ashton F. Serogroup B, electrophoretic type 15 Neisseria meningitidis in Canada. J Infect Dis 1998;177:1754-7. (Pubitemid 28243611)
40. Tyler S, Tsang R. Genetic analysis of Canadian isolates of C:2a:P1.2,5 and B:2a:P1.2,5 Neisseria meningitidis strains belonging to the hypervirulent clone of ET-15. Can J Microbiol 2004;50:433-43. (Pubitemid 39248678)
41. Harrison LH, Jolley KA, Shutt KA, et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 2006;193:1266-74.
42. Keyserling HL, Pollard AJ, DeTora LM, Gilmet GP. Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. Expert Rev Vaccines 2006;5:445-59. (Pubitemid 44627876)
43. Law DKS, Stoltz J, Henderson AM, Tsang RSW. Antigenic and genetic characterization of serogroup C meningococci isolated from invasive meningococcal disease cases in Canada from 1999 to 2003. Can J Microbiol 2005;51:523-30. (Pubitemid 41719735)
44. Law DKS, Lorange M, Ringuette L, et al. Invasive meningococcal disease in Québec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 2006;44:2743-9. (Pubitemid 44228566)
45. Tsang RSW, Tsai CM, Henderson AM, et al. Immunochemical studies and genetic background of two Neisseria meningitidis isolates expressing unusual capsule polysaccharide antigens with specifities of both serogroup Y and W135. Can J Microbiol 2008;54:229-34. (Pubitemid 351398621)
46. National Advisory Committee on Immunization. Statement on recommended use of meningococcal vaccines. Canada Communicable Disease Report 2001;27(ACS-6):2-36.
47. Tsang RSW, Squires SG, Tam TWS. Characterization of Neisseria meningitidis strains isolated from invasive meningococcal disease cases in Canada in 2001. Can J Microbiol 2003;49:633-8. (Pubitemid 38197836)
48. Maiden MC. Population structure of Neisseria meningitidis. In: Ferreiros C, Criado MT, Vazquez J, eds. Emerging strategies in the fight against meningitis: Molecular and cellular aspects. Norwich, UK: Horizon Scientific Press, 2002:151-70.
49. Hoang LMN, Thomas E, Tyler S, et al. Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin Infect Dis 2005;40:e38-42.
50. Claus H, Matsunaga W, Vogel U. Molecular discrimination between Neissseria meningitidis serogroups W-135 and Y based on the nucleotide recognition domain sequence of the capsule polymerases. J Clin Microbiol 2010;48:3459-60.